Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up

2010-05-01

Annals of Oncology , Volume 21 - Issue SUPPL. 5

Additional Metadata
Keywords	Cushing syndrome, Europe, article, bronchus carcinoid, bronchus tumor, cancer classification, cancer staging, carcinoid, chromogranin A, cisplatin, clinical trial, cyclophosphamide, doxorubicin, etoposide, fluorouracil, follow up, human, large cell carcinoma, lung small cell cancer, lung tumor, neuroendocrine tumor, practice guideline, priority journal, prognosis, risk assessment, somatostatin derivative, somatostatin receptor, survival rate, temozolomide, thymoma, treatment response, tumor recurrence, tumor regression, vincristine
Persistent URL	doi.org/10.1093/annonc/mdq191, hdl.handle.net/1765/20747
Journal	Annals of Oncology
Note	Free full text at PubMed
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Öberg, K., Hellman, P., Kwekkeboom, D., & Jelic, S. S. (2010). Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(SUPPL. 5). doi:10.1093/annonc/mdq191

Publication